

cancer52

the common voice for
rare & less common cancers

Cancer52 is registered as
a charity in England and Wales,
Charity No. 1174569 and as a
company limited by guarantee
in England and Wales,
Company No. 07994413

Annual Review

& Financial Statements

1 Apr 2021 – 31 Mar 2022

cancer52.org.uk

Contents

WELCOME: TRUSTEES ANNUAL REPORT AND DIRECTORS REPORT FOR THE YEAR ENDED 31ST MARCH 2022

Foreword	3
Welcome to our Annual Review 2021–2022	3

STRENGTH IN UNITY: OUR PRINCIPLES	4
Our core principles	4

UNITING WITH ONE VOICE: WHO WE ARE	5
The Cancer52 team	5
Our charity members	5
The Impact of Covid-19	5

MAKING THE CANCER52 VOICE HEARD	6
Informing, advising and supporting our members	6

PARTNERSHIP: REPRESENTATION AND ADVOCACY IN POLICY	8
---	----------

PARTNERSHIP: COLLABORATION ON BEHALF OF THE PATIENTS	10
Informing our stakeholders	12

MAKING THE VOICE OF PEOPLE WITH RARE AND LESS COMMON CANCERS HEARD: OUR HEADLINE ACHIEVEMENTS FOR 2021–2022	13
Partnership	13
Policy	13
Patients	13

FUNDING	14
The value of our support	14
Voluntary member donations	14
Support from industry	14

FUTURE PLANS	15
---------------------	-----------

THE ACOUSTICS: STRUCTURE AND CONSTITUTION	16
Structure and governance	16
Purpose	16
Public benefit	16
Board and management operations and structure	17

MONEY TALKS: FINANCIAL REVIEW 2020–2021	19
--	-----------

INDEPENDENT EXAMINERS' REPORT TO THE TRUSTEES OF CANCER52	20
Independent examiner's report to the trustees of Cancer52	20
Section A	22
Section B	23
Section C	24

ADMINISTRATIVE DETAILS	35
-------------------------------	-----------

REFERENCES	36
-------------------	-----------

LIST OF CHARITY MEMBERS 2020–2021	37
--	-----------

Welcome:

Trustees Annual Report and Directors Report for the year ended 31st March 2022



Foreword

The year 2022 marks my seventh and final year as Chair of **Cancer52**. As I look back, I've been proud to witness the organisation grow in stature. It successfully built on its core remit, to advance collaborative policy leadership for the rare and less common cancer community, all while maintaining steadfast support for its members, enabling them to navigate challenges together, including a health system and Government still in the throes of dealing with the COVID-19 pandemic.

Laying this groundwork means **Cancer52** is ready for an exciting future of further expansion and widening influence.



Jonathan Pearce, Chair

Welcome to our Annual Review 2021-22

We are delighted to welcome readers to this Annual Review, which covers the year to the end of March 2022.

It has been a challenging year but we have grown our membership and our influence and worked with a widening group of stakeholders to deliver ever more ambitious projects. All of this could only have been achieved with our small but dedicated and committed team, and my thanks to them.

And now – as the world opens up again to human rather than technological interaction – our opportunities to network and share our aims and values are growing. With the help of our many partners we will continue to deliver on projects and activities that help build the voice of the hundreds of thousands of people with a rare or less common cancer.

My thanks to Jonathan for his ongoing support over the years. We will miss him as chair but are delighted that he will stay on as a trustee.

Finally huge thanks to all those working within the NHS to support people with a rare or less common cancer. We salute your dedication, knowledge, and work ethic.



Jane Lyons, CEO



Strength in unity: our principles

Cancer52 is a national organisation, created in 2007 by Professor Sir Mike Richards, CBE, then National Cancer Director, and was registered as a charity in England and Wales in September 2017.

We are a unifying body for charitable and not-for-profit organisations working in the field of rare and less common cancers. We represent well over 100, predominantly small, patient-support and research-focused cancer charities and organisations.

Cancer52 gets its name from when rare and less common cancers accounted for 52% of all cancer deaths in the UK, despite the fact that only 47% of cancers diagnosed in England are of this type.¹ In 2020, this shifted to 47% of diagnoses yet 55% of cancer deaths.²

Our member charities and organisations are united in seeking a better future for everyone affected by rare and less common cancers. We provide a collective voice to champion earlier diagnosis, better treatment, better representation, funding and support for people with cancers other than the four most common cancers (breast, lung, bowel and prostate). **Cancer52** ensures the voice of people with rare and less common cancers does not go unheard.



Our core principles

Our aim

Our primary aim is to promote improved diagnosis, treatment and support for those affected by rare and less common cancers.

Our mission

Our mission is to provide a strong, unified voice for rare and less common cancer organisations by representing, speaking, informing, sharing and involving our members in achieving our vision.

Our vision

Our vision is to see an end to the inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases compared with the four most common cancers.

Our values

Everything we do is underpinned by our values, which are to be:

- ambitious | outcomes-focused |
- collaborative | evidence-based | influential
- and to behave with honesty and integrity.

Uniting with one voice: who we are

Cancer52 aims to better represent people with rare and less common cancers at a senior policy and decision-making level. Sourcing and bringing together the knowledge and expertise of our many members makes this possible.

The Cancer52 team

During the year ending 31 March 2022, the core team consisted of:

- Jane Lyons, CEO: Responsible for the overall running of the charity.
- Ainsley Taylor, Operations Manager: Supporting the CEO on governance, finance, fundraising, administration and the co-ordination of membership donations, recruitment, and supporting the Trustees.
- Stephanie Judycki, Communications Executive: Leads on internal and external communications including member e-bulletins, Cancer52 website, and social media.

Our Board of Trustees is listed on page 35.

Consultants, Laura Thomas and Jennifer Mitchell, from Brighter Together Consulting worked with us on policy and Jason Dennis ran our finances.

Thanks to you all for your hard work and dedication.

Our charity members

Our members are united in their determination to improve treatment and outcomes for their individual patient groups.

They are mostly small but fiercely dedicated organisations that offer patient support, often with a research focus.

The vast majority (75%) of our membership have an annual income of less than £1 million, with 67% on an income of less than £500,000 and 38% with an income of less than £100,000. Almost all our members offer patient support and over two-thirds invest in research.³

The full list of **Cancer52's** members for the financial year 2021-22, can be seen on page 37.

Our active membership continues to grow, and during the financial year 2021-22, 10 new charities of varying sizes joined Cancer52. We happily welcomed: *Live Through This, Leukaemia UK, North West Cancer Research, Paul's Cancer Support Centre, Penny Brohn UK, The Charley Ashton Foundation, The Myrovlytis Trust, The Urology Foundation, ThymicUK, and Wendy Gough Cancer Awareness Foundation.*

We hugely value and appreciate our members' ongoing dedication and commitment to **Cancer52**.

The impact of Covid-19

Despite Covid-19's continued impact we maintained a high level of engagement with our members and their patient groups during the slow return to normal.

We are proud of our ongoing learning and how we have adapted to deeply challenging and complex circumstances across the health system, especially when Covid relief funds were wound down.

Helping members keep patients informed

While we join others in welcoming the gradual return to new normal, our focus remains on the threat of infection for patients who are immunosuppressed.

Cancer52, among other charities, supported the Deputy Chief Medical Officer (DMCO) and Department of Health and Social Care (DHSC) in England to cascade critical information to the public. We knew that shielding was a key issue for those living with cancer so joined the DHSC Shielding Advisory Group meetings to help share salient information on any changes in shielding advice.

Making the Cancer52 voice heard

We work tirelessly to support people with rare and less common cancers and to ensure we have a strong presence in the rare and less common cancer community.

- We are represented at the highest level on boards and task forces.
- We value close teamwork and collaboration.
- Our flexible structure allows us to utilise a range of skills and methods to help our members support patients.

From telephone conversations and surveys to seats on influential national cancer bodies, we take every opportunity to represent people with rare and less common cancers.

Informing, advising and supporting our members

Regular e-bulletins kept our members informed and bimonthly virtual meetings offered a chance to voice any questions and concerns and communicate shared learnings. New monthly virtual CEO Meetings linked together CEOs on higher level activities.

Meeting with our members

Our virtual meetings remain in place, as over the year they empowered charities from across the country to connect, and quickly and easily share information.



376

individuals attending
All Member Meetings



150+

attended one of our many
working group meetings



200+

people attended our
monthly CEO meetings

Sharing

We want everyone with rare and less common cancers to have the chance to be best supported and make informed choices. We consistently encourage our members to talk to each other and the resulting knowledge exchange means that even those supported by charities with limited resources have access to continuing flow of useful information.

Creating collaboration helps charities from duplicating effort and frees up resources to better support people with cancer. We know that a collaborative voice is a stronger voice.

'I'm very impressed by everything that you're doing at the moment – Cancer52 is certainly having a big impact and we are proud to be a member.'

Lydia Makaroff, CEO, Fight Bladder Cancer

Regular members' e-bulletin

Throughout this financial year, our weekly or biweekly e-bulletin updated our members on:

- Dates and details of Cancer52 meetings and meetings by member charities or national organisations;
- Updated information for sharing with patients;
- Opportunities to get involved with projects that support people with rare and less common cancers;

We want everyone with rare and less common cancers to have the chance to be best supported and make informed choices.

- Patient surveys;
- Projects where members wanted to share learning or to raise awareness
- Member and NHS Cancer Programme job vacancies
- Training courses
- NHS and other cancer charity webinars
- Developments in health policy pertinent to cancer, such as the DHSC 10-Year Cancer Plan

The e-bulletins have an average 40% open rate and 8.3% click-through rate, which is significantly more than the industry average.⁴ It shows members prize our bulletins as a useful and efficient way of disseminating information so that they and their patients are aware of critical events, activities and developments.

'Thank you Cancer52 for your sterling work for the cause of the rare and less common cancer communities.'

Helen Morement, CEO, AMMF

CANCER52 ALL MEMBER MEETINGS

Fortnightly virtual meetings continued throughout the financial year. They offer ideal networking opportunities and the chance to help patients by learning from interesting and thought-provoking speakers. Meetings were warmly welcomed and well attended, most notably the launch of the "DoYouCUs?" Campaign, which attracted nearly 50 attendees.

The meetings are great relationship builders and boost the profile of people with rare and less common cancers.

CEO CALLS AND MEETINGS

Monthly video calls started in August 2020 and provide member CEOs direct access to their peers. These meetings have become incredibly valuable opportunities to raise problems, talk through ideas, share best practice or discuss ways of increasing awareness and boosting the sector's profile.

'Cancer52 has created our network, fab having peers we can reach. We have a real sense of community.'

Liz Darlison, CEO, Mesothelioma UK

WORKING GROUPS

Some of our members face similar challenges in supporting people with cancer so we set up additional working groups on specific shared areas. New groups examined cancer-related menopause, health inequalities, IBS (by way of misdiagnosis), and the NHS website cancer pages.



Partnership: Representation and advocacy in policy

Cancer52 represents its members at the highest level and acts as a conduit to organisations that need to hear the patient voice of people with rare and less common cancers. As a strong and determined alliance, we can make more noise about the need for improvements in cancer services, including those supported by our member charities.

During 2021–2022, we were invited to sit on several NHS England (NHSE) boards and groups where we used our influence to oversee, advise on and implement the NHS Long Term Plan (LTP)⁵ for cancer.

HEALTH AND SOCIAL CARE SELECT COMMITTEE

Cancer52 responded to two Health and Social Care Select Committee Inquiries: Cancer Services and Clearing the Backlog Caused by the Pandemic.⁶ **Cancer52's** CEO, Jane Lyons, contributed evidence at an oral hearing of the inquiry into cancer services. The resulting Health and Social Care Committee Report on Cancer services made key recommendations using **Cancer52's** evidence, including recommending an action plan for rare and less common cancers.⁷

CANCER CHARITIES

Cancer52 also works collaboratively with many charities outside its direct membership where this has more impact for people living with cancer.

A key example of this is the One Cancer Voice (OCV) initiative where over 50 charities work together on fundamental policy asks such as investing in the workforce that helps people with cancer, and increasing spend on diagnostics. We sit on the steering group and instigated and provided the structure and pro bono time to develop the pan cancer charity

response to the Cancer Plan call for evidence in spring 2022.⁸

CANCER52 POLICY AND PUBLIC AFFAIRS STEERING GROUP

Our Policy and Public Affairs Steering Group (PPASG) met frequently to exchange information and help formulate **Cancer52's** policy asks. They helped to inform our responses to the Cancer Plan call for evidence and Health and Social Care Select Committee inquiries. During 2020–2021 this group was chaired by Chris Walden, **Cancer52** Trustee and Deputy Director of Policy, Campaigns and Engagement at Blood Cancer UK, with vice chair Bradley Price, Policy and Public Affairs Manager of Sarcoma UK. The discussions help develop **Cancer52** policy.

CANCER52 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) WORKING GROUP ACCESS TO MEDICINES WORKING GROUP

This group convenes whenever issues impact several **Cancer52** members, most often looking at the role of patients in NICE processes and the ability to get the patient voice heard at NICE.⁹

10-YEAR CANCER PLAN

Early in 2022 we were invited to join a round table hosted by the then Secretary of State for Health and Social Care, the Rt Hon Sajid Javid MP, where he launched a call for evidence for his new 10-year plan for cancer.¹⁰

At time of writing the Plan is still being developed while ministerial appointments settle.

Cancer52 led the pan cancer charity collaboration, worked with members (including surveying members online) and other charities to help draft our own response and attended various evidence-gathering meetings hosted by the DHSC. To push views of people with rare and less common cancers into the spotlight we commissioned a patient survey and incorporated the findings from 259 patients into our response.¹¹

259

We commissioned a patient survey and incorporated the findings from 259 patients into our response



The Pan Cancer Charity Collaboration

Partnership: Collaboration on behalf of patients

MAKING THE VOICE OF PEOPLE WITH RARE AND LESS COMMON CANCERS HEARD

Working closely with the pharmaceutical company Pfizer, **Cancer52** launched the awareness raising campaign Do You C Us? in the summer of 2021. A campaign website was created featuring facts and figures and patient videos.¹² The campaign was launched virtually at a parliamentary event hosted by Paul Bristow MP and joined by **Cancer52** members and other MPs. The team also worked to secure press and social media coverage.

Working collaboratively across the NHS

WORKING WITH THE NHS CANCER PROGRAMME

NATIONAL CANCER BOARD

Alongside Cancer Research UK and Macmillan Cancer Support, we have a place on the NHSE National Cancer Board. Together we provide strategic leadership across the healthcare sector in the delivery of the cancer ambitions inside the NHS Long Term Plan.⁵

Cancer52 also holds a place on the following NHSE cancer programme groups:

- Cancer Campaigns Oversight Group;
- Early Detection Task and Finish Group;
- The Cancer Patient Experience Survey Advisory Group;
- The Cancer Patient Experience Survey Reporting Sub Group;
- NHSE Cancer Charity Forum;

NHSE'S HELP US, HELP YOU CAMPAIGN

Cancer52 helped ensure that the voice of people with rare and less common cancers were heard in this national cancer symptom awareness campaign. **Cancer52** worked with partners in NHSE to drive interest amongst members and then facilitate their involvement. As a result, NHSE collaborated with the following **Cancer52** members on the Clear on Cancer – Help Us, Help You national campaign to create co-branded stills and videos:

- Fight Bladder Cancer;
- Bone Cancer Research Trust;
- It's on the Ball
- Leukaemia UK
- Brain Tumour Charity

Cancer52 helped ensure that the voice of people with rare and less common cancers were heard in this national cancer symptom awareness campaign.



Don't let cancer play on your mind

Clear on cancer

**BONE
CANCER
RESEARCH TRUST**
UNTIL THERE'S A CURE

Working collaboratively across the wider cancer community

We also worked closely with a number of other organisations within the UK cancer community where it served the purpose of ensuring the voice of people with rare and less common cancers was better heard.

CHARITY MEDICINES ACCESS COALITION (CMAC)

Many people need quicker access to new and innovative medicines. This umbrella group of charities works to find a long-term solution to this problem. We are grateful to member charities for representing us on this Coalition.

CHILDREN AND YOUNG PEOPLE CANCER COALITION

Many of our member charities support children and young people with cancer and these charities have formed the Children and Young People Cancer Coalition. We sit on the steering group and support the work of charities in this field.

NATIONAL VOICES

This wide-ranging coalition of healthcare charities helps us engage where topics are particularly relevant to people with rare and less common cancers.

SPECIALISED HEALTHCARE ALLIANCE

This Alliance campaigns on behalf of those with rare and complex conditions. **Cancer52** is a member and attends briefings on wider topics affecting people with rare cancers.

THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY

Our CEO sits on the newly formed ABPI Patient Advisory Council.

The ABPI holds quarterly meetings of its Patient Organisation Forum. We join the briefings alongside other charities and sit on the steering group that plans the meetings and organises speakers.

In February 2022, **Cancer52** worked with the Association of the British Pharmaceutical Industry (ABPI) on an Anti-Microbial Resistance campaign specific to people living with rare and less common cancers called Together for Antibiotics.^{13,14}



Informing our stakeholders

Collectively, and also as our member representatives, we are in ongoing communication with members of other charities, NHS professionals and administrators, and anyone who has influence in the rare and less common cancer field.

Cancer52 Annual Stakeholder Meetings

Our annual Stakeholder Meeting offers a great opportunity for all our members to engage with senior level speakers and industry representatives.

Due to the ongoing COVID-19 pandemic the Annual All Stakeholder Meeting was held virtually in October 2021. The theme was Early Diagnosis, and it was attended by 75 delegates representing members, industry, the Government and NHS.

For the first time in two years, we plan to go back to an in-person event for October 2022.

Website

Our website acts as a central point for information and spreads the message that patient experience, treatment and outcomes will only improve with more time, money and effort focused on coping with rare and less common cancers.

The site includes links to all member organisations, plus the sponsors and groups we collaborate with to offer a useful portal for sharing information between members, patients, and the general public. We posted reports on our activities during the year and featured a news stream of prominent issues.

Website users can access reports together with informative videos, announcements of upcoming conferences or meetings, contact and donation opportunities.

Social media and media

We have been especially active during this year on Facebook and Twitter, gathering a total of 2,500 followers to date. We use our social media channels to distribute new information, react to events and communicate with our members. We excel at supporting member charities on Twitter by reposting their awareness campaigns and fundraising activities and facilitating engagement with patients. This can be especially effective to amplify awareness of a rare or less common type of cancer by tagging several members into a post to help create a unified voice for patients.





Making the voice of people with rare and less common cancers heard: our headline achievements for 2021–2022

We are proud of our achievements during what has been a challenging year for us, our members and the NHS.

Partnership

INFORMING, SHARING WITH, AND EMPOWERING OUR MEMBERS

We are grateful for the engagement and significant positive feedback from our members. This confirms that our redoubled efforts to improve our communications through our e-bulletins, All Member Meetings, CEO calls and meetings, group meetings, patient surveys, CEO survey and CEO briefings have been well received.

Our membership and engagement levels increased significantly.

Policy

RESPONDING COLLECTIVELY TO THE CHANGING POLITICAL CANCER PRIORITIES

We continue to work alongside NHSE Cancer Programme to improve outcomes for those with rare and less common cancers and to meet the early diagnosis target of diagnosing 75% of all cancers at stage I and II by 2028. We also worked collaboratively with our members and the wider cancer charity community to respond effectively to the Government's 10-year Cancer Plan Call for Evidence.

Patients

ADVOCATING FOR THOSE AFFECTED BY RARE AND LESS COMMON CANCERS THROUGH COLLABORATION

We raise the profile of patients with a rare and less common cancer by consistently taking the patient voice to influencers and policy makers. We have a unique place in the cancer community and take every opportunity to make this patient voice heard.



Our support: sources of funding

In 2021–2022, we received funding from a variety of sources: donations from members; individual donations; and support from pharmaceutical companies.

The value of our support

We equally appreciate the valuable time, expertise and energy generously donated by our members.

We are hugely grateful to every donor and supporter for their financial support which helps propel us towards achieving our objectives. The financial benefaction of our charity members represents a very significant contribution in terms of the number and variety of organisations that support **Cancer52**.

Voluntary member donations

The vast majority of our financial supporters are our member charities from whom we request a voluntary donation to our work that is aligned to their income. We aim to offer free membership to smaller charities with financial challenges although, in many cases, they contribute as they value the work we do together.

Despite the continuing the Covid-19 pandemic, donations totalled £27,950 from 45 member charities and, although we continued to waive donations to all member charities with an income of less than £500,000, membership donations for 2021/22 exceeded those of 2020/21.

Individual donations

Donations are welcome from any individuals or organisations who recognise the value of our contribution to supporting people with rare and less common cancers.

During the financial year 2021-22, **Cancer52** received almost £19,000 from a variety of platforms and individuals.

Support from industry

In 2021–2022 we received support from Abbvie, BMS, Gilead, GSK, Ipsen, Roche, Sanofi and Takeda, who all benefited from membership of **Cancer52's** Corporate Supporter Programme.

Cancer52 has a clear policy when working with the pharmaceutical industry and abides by industry guidelines.⁶ Some 62.7% of our funding comes from pharmaceutical companies. This comprises support for specific projects as well as unrestricted support.

We believe all our industry partners recognise the value of dealing with an umbrella body that channels one voice for rare and less common cancers.

Working with **Cancer52** offers a unique opportunity to engage with the voice of people with rare and less common cancers, and benefit from the expertise and knowledge gained through our relationships with member organisations.



Future plans

Cancer52 is proud of its achievements during this unprecedented year. Our major objectives prevail and we will take them forward into 2022–2023.

We will provide a strong, unified voice to promote improved diagnosis, treatment and support for those affected by rare and less common cancers so that we see an end to inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases.

In three years' time, Cancer52 will:



UK wide

Be a well-resourced organisation making the voice of rare and less common cancers heard across the four nations of the UK wherever decisions are taken on the treatment and care of people with these cancers.



Leadership

Have retained its market leadership position but built its thought leadership and increased its collaborative work with fellow cancer charities and alliances.



Alignment

Have reviewed its target audiences and brand name and, if necessary, be ready to take steps to change it.

Inequalities focus

Have retained its focus on its aim, mission and values whilst placing reducing inequalities at the heart of everything it does



The acoustics: structure and constitution




Structure and governance

Cancer52 is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales. It is governed by its Memorandum and Articles of Association, and the work, management, finances and strategy of the charity are overseen by a Board of Trustees, who are also the company directors. The Trustees who held office during the financial year and at the date of the report are set out on page 35.

Under the Articles of Association, a minimum of three trustees and a maximum of twelve trustees can be in office. At Annual General Meetings, one-third of the existing directors must retire by rotation based on the longest serving directors retiring first. Retiring directors may be re-appointed at Annual General Meetings by the vote of existing directors. New directors may only be appointed at Annual General Meetings where the notice and approval requirements set out in the Articles of Association have been satisfied.

The Board has agreed that the usual term of tenure for trustees should be a maximum of two terms of three years each (six years in total), with review and approval by the Board at the end of each term of tenure. In exceptional circumstances, and in order not to lose important or valuable skills, experience and expertise, trustees may serve for a third term of tenure, subject to the approval of the Board. Trustees do not receive remuneration for their duties.



Purpose

The charity's purposes are set out in its Memorandum and Articles of Association as follows:

To promote and protect the health of people with rare and less common cancers by:

1. Advancing and promoting understanding, awareness, research and learning about rare and less common cancers;
2. Acting as a collective voice and advocating for the needs of individuals affected by a rare or less common cancer in order to improve diagnosis, treatment and long-term support outcomes; and
3. Supporting, representing and empowering not-for-profit organisations working in the field of rare and less common cancer.

Public benefit

Our work delivers public benefit by providing information and support to people diagnosed with, treated for or living with a rare or less common cancer through the services, interactions and collaboration that we facilitate between our members. We drive change and enhancements in the cancer system to improve outcomes for people affected by a rare or less common cancer.

As part of our business planning processes, we review our aims and objectives each year, which includes looking at what we have achieved in previous years, and how our activities have benefited those groups of people we were set up to help. We have referred to the Charity Commission's general guidance on public benefit when reviewing our aims and objectives, and in planning our work for the future.

Board and management operations and structure

Board of Trustees

The Board of Trustees meets at least four times a year to review the organisation's work, finances and services, and to agree strategic goals for the charity. Board meetings were virtual throughout 2021–2022 and invited the Chief Executive and the Operations Manager and others as appropriate.

The chair and other trustees with financial expertise also meet separately with the Chief Executive, Operations Manager, and the charity's accountant on a quarterly basis to monitor and scrutinise the charity's financial strategy and operations and make any necessary recommendations to the full Board of Trustees.

Recruitment and appointment of new trustees

Following the resignation of two trustees in 2020, the Board decided not to recruit and appoint new trustees during the Covid-19 pandemic. However, in Spring 2021, a schedule and criteria to recruit new trustees was implemented.

Our recruitment drive welcomed in five new Trustees, Anna Evans, Catherine Hodgson, Dr Max Brodermann, Michael Draeger and Sophie Davies. Each brought a wealth of knowledge and insight to the Board.

In March 2022, Catherine Hodgson resigned from the Board of Trustees as a result of leaving the sector to pursue other avenues. We pass our thanks to Catherine for her contribution to the Board during her time with us.

Related parties

The only related parties are considered to be the trustees and those connected with the trustees, including their close families, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

Risk assessment and management

The Board of Trustees and the chief executive maintain a risk register and assess risks on an annual basis. The trustees are satisfied that the major risks to the organisation have been accurately identified and that appropriate systems and procedures for managing those risks are in place.

Safeguarding

We have a strong commitment to protecting and promoting the health, wellbeing and safety of all engaged in our work. While we are not a patient representative charity, we still adhere to good safeguarding practice. Our Safeguarding Policy is reviewed each year and is accessible on the Governance section of our website. All new staff and volunteers are required to participate in a full day safeguarding training course, provided by an external organisation.

Annual review

The Annual Review 2021–2022 was completed and disseminated, with thanks to the Board nominees Chris Walden and Helen Morement, and to external copywriter and designers.



cancer52

the common voice for
rare & less common cancers



Money talks: financial review 2021-2022

Financial statement

As shown in the statement of financial activities on the following pages, in the year 2021–2022:

- reserves brought forward from 2020–2021 were £116,730
- income for the financial year was £144,709
- expenditure for the current financial year was £151,150, resulting in a small, anticipated deficit of £6,441
- reserves of £110,289 were available at the end of the 2021–2022 financial year

Reserves policy

The Board of Trustees' strategy on reserves is for the organisation to maintain sufficient funds to cover the operational running costs in the event of a major setback. This means that we aim to hold approximately six months' annual expenditure in reserve.

At the end of the 2021–2022 financial year, our reserves stood at £110,289, which adequately covers the six months required.

The Company has taken advantage of the small companies' exemption in preparing this report. The trustees declare that they have approved the trustees' report (including directors' report) above.

Signed on behalf of the charity's trustees/directors

Signature _____

Jonathan Pearce

Trustee / Director

Date _____

Signature _____

Nic Puntis

Trustee / Director

Date _____



Section A

Independent Examiner's Report

Report to the
trustees/directors/
members of

Cancer 52

On accounts for the year
ended

31st March 2022

Charity no.:

1174569

Company no.:

07994413

Set out on pages

22 To 34

Responsibilities and
basis of report

I report to the charity trustees on my examination of the accounts of the Company for the year ended **31st March 2022**.

As the charity's trustees of the Company (who are also the directors of the company for the purposes of company law), you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited for this year under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ("the 2011 Act"). In carrying out my examination, I have followed the Directions given by the Charity Commission (under section 145(5)(b) of the 2011 Act).

Independent
examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below *) which gives me cause to believe that:

- accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
- the accounts do not accord with such records; or
- the accounts do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the accounts have not been prepared in accordance with the Charities SORP (FRS102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

** Please delete the words in the brackets if they do not apply.*

Signed:

Date:

21st July 2022

Name: Jason Dennis

Relevant professional qualification(s) or body (if any): AAT - Association of Accounting Technicians
ATT – Association of Taxation Technicians

Address: 31 Clover Way, Paddock Wood, Tonbridge, Kent TN12 6BQ

Section B

Disclosure

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose.

Section A

Statement of financial activities

(including summary income and expenditure account)

Recommended categories by activity

Income (Note 3)

Income and endowments from:

Donations and legacies

Total

Expenditure (Notes 4)

Expenditure on:

Raising funds

Charitable activities

Other

Total

Net income/(expenditure) before tax for the reporting period

Tax payable

Net income/(expenditure) after tax before investment gains/(losses)

Net gains/(losses) on investments

Net income/(expenditure)

Extraordinary items

Transfers between funds

Other recognised gains/(losses):

Gains and losses on revaluation of fixed assets for the charity's own use

Other gains/(losses)

Net movement in funds

Reconciliation of funds:

Total funds brought forward

Total funds carried forward

Guidance Note

	Unrestricted funds £ F01	Restricted income funds £ F02	Endowment funds £ F03	Total funds £ F04	Prior year funds £ F05
S01	144,709	-	-	144,709	175,695
S07	144,709	-	-	144,709	175,695
S08	-	-	-	-	1,125
S09	148,750	-	-	148,750	123,103
S11	2,400	-	-	2,400	1,800
S12	151,150	-	-	151,150	126,028
S13	(6,441)	-	-	(6,441)	49,667
S14	-	-	-	-	-
S15	(6,441)	-	-	(6,441)	49,667
S16	-	-	-	-	-
S17	(6,441)	-	-	(6,441)	49,667
S18	-	-	-	-	-
S19	-	-	-	-	-
S20	-	-	-	-	-
S21	-	-	-	-	-
S22	(6,441)	-	-	(6,441)	49,667
S23	116,730	-	-	116,730	67,063
S24	110,289	-	-	110,289	116,730

Section B

Balance sheet (as at 31st March 2021)

	Guidance Note	Unrestricted funds £	Restricted income funds £	Endowment funds £	Total this year £	Total last year £
Current assets						
Cash at bank and in hand (Note 24)	B09	135,949	-	-	135,949	118,530
Total current assets	B10	135,949	-	-	135,949	118,530
Creditors: amounts falling due within one year (Note 20)	B11	25,660	-	-	25,660	1,800
Net current assets/(liabilities)	B12	110,289	-	-	110,289	116,730
Total assets less current liabilities	B13	110,289	-	-	110,289	116,730
Total net assets or liabilities	B16	110,289	-	-	110,289	116,730
Funds of the Charity						
Endowment funds (Note 27)	B17	-			-	-
Restricted income funds (Note 27)	B18		-		-	
Unrestricted funds	B19	110,289		-	110,289	116,730
Revaluation reserve	B20				-	
Fair value reserve	B21					
Total funds	B22	110,289	-	-	110,289	116,730

The company was entitled to exemption from audit under s477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to small companies subject to the small companies regime and in accordance with FRS102 SORP.

Signed by one or two trustees/directors on behalf of all the trustees/directors

Print Name	Date of approval dd/mm/yyyy
Jonathan Pearce	
Nic Puntis	

Signature of director authenticating accounts being sent to Companies House

Signature	Date dd/mm/yyyy
Jonathan Pearce	
	Print name

Section C

Notes to the accounts

NOTE 1: Basis of preparation

This section should be completed by all charities.

1.1 Basis of accounting

These accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

The accounts have been prepared in accordance with:

- and with*

✓

 the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014
- and with*

✓

 the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102)
- and with the Charities Act 2011.

The charity constitutes a public benefit entity as defined by FRS 102.*

✓

* -Tick as appropriate

1.2 Going concern

If there are material uncertainties related to events or conditions that cast significant doubt on the charity's ability to continue as a going concern, please provide the following details or state "Not applicable", if appropriate:

An explanation as to those factors that support the conclusion that the charity is a going concern;

Not applicable

Disclosure of any uncertainties that make the going concern assumption doubtful;

Not applicable

Where accounts are not prepared on a going concern basis, please disclose this fact together with the basis on which the trustees prepared the accounts and the reason why the charity is not regarded as a going concern.

Not applicable

1.3 Change of accounting policy

The accounts present a true and fair view and no changes have been made to the accounting policies adopted in note { }.

Yes*

✓

No*

--

* -Tick as appropriate

Please disclose:

<i>(i) the nature of the change in accounting policy;</i>	Not applicable
<i>(ii) the reasons why applying the new accounting policy provides more reliable and more relevant information; and</i>	Not applicable
<i>(iii) the amount of the adjustment for each line affected in the current period, each prior period presented and the aggregate amount of the adjustment relating to periods before those presented, 3.44 FRS102 SORP.</i>	Not applicable

1.4 Changes to accounting estimates

No changes to accounting estimates have occurred in the reporting period (3.46 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

Please disclose:

<i>(i) the nature of any changes;</i>	Not applicable
<i>(ii) the effect of the change on income and expense or assets and liabilities for the current period; and</i>	Not applicable
<i>(iii) where practicable, the effect of the change in one or more future periods.</i>	Not applicable

1.5 Material prior year errors

No material prior year error have been identified in the reporting period (3.47 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

Please disclose:

<i>(i) the nature of the prior period error;</i>	Not applicable
<i>(ii) for each prior period presented in the accounts, the amount of the correction for each account line item affected; and</i>	Not applicable
<i>(iii) the amount of the correction at the beginning of the earliest prior period presented in the accounts.</i>	Not applicable

NOTE 2: Accounting policies

2.1 INCOME

Recognition of income

These are included in the Statement of Financial Activities (SoFA) when:

- the charity becomes entitled to the resources;
- it is more likely than not that the trustees will receive the resources;
- the monetary value can be measured with sufficient reliability.

Yes*	No*	N/a*
<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Offsetting

There has been no offsetting of assets and liabilities, or income and expenses, unless required or permitted by the FRS 102 SORP or FRS 102.

Yes*	No*	N/a*
<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Grants and donations

Grants and donations are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP).

Yes*	No*	N/a*
<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

In the case of performance related grants, income must only be recognised to the extent that the charity has provided the specified goods or services as entitlement to the grant only occurs when the performance related conditions are met (5.16 FRS 102 SORP).

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Legacies

Legacies are included in the SoFA when receipt is probable, that is, when there has been grant of probate, the executors have established that there are sufficient assets in the estate and any conditions attached to the legacy are either within the control of the charity or have been met.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Government grants

The charity has received government grants in the reporting period

Yes*	No*	N/a*
<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

Tax reclaims on donations and gifts

Gift Aid receivable is included in income when there is a valid declaration from the donor. Any Gift Aid amount recovered on a donation is considered to be part of that gift and is treated as an addition to the same fund as the initial donation unless the donor or the terms of the appeal have specified otherwise.

Yes*	No*	N/a*
<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Contractual income and performance related grants

This is only included in the SoFA once the charity has provided the related goods or services or met the performance related conditions.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Donated goods

Donated goods are measured at fair value (the amount for which the asset could be exchanged) unless impractical to do so.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt and they are recognised on receipt. In the reporting period in which the stocks are distributed, they are recognised as an expense at the carrying amount of the stocks at distribution.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Donated goods for resale are measured at fair value on initial recognition, which is the expected proceeds from sale less the expected costs of sale, and recognised in 'Income from other trading activities' with the corresponding stock recognised in the balance sheet. On its sale the value of stock is charged against 'Income from other trading activities' and the proceeds from sale are also recognised as 'Income from other trading activities'.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Goods donated for on-going use by the charity are recognised as tangible fixed assets and included in the SoFA as incoming resources when receivable.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Gifts in kind for use by the charity are included in the SoFA as income from donations when receivable.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Donated services and facilities	Donated services and facilities are included in the SoFA when received at the value of the gift to the charity provided the value of the gift can be measured reliably.	Yes*	No*	N/a*
				✓
	Donated services and facilities that are consumed immediately are recognised as income with an equivalent amount recognised as an expense under the appropriate heading in the SoFA.	Yes*	No*	N/a*
				✓
Support costs	The charity has incurred expenditure on support costs.	Yes*	No*	N/a*
			✓	
Volunteer help	The value of any voluntary help received is not included in the accounts but is described in the trustees' annual report.	Yes*	No*	N/a*
				✓
Income from interest, royalties and dividends	This is included in the accounts when receipt is probable and the amount receivable can be measured reliably.	Yes*	No*	N/a*
		✓		
Income from membership subscriptions	Membership subscriptions received in the nature of a gift are recognised in Donations and Legacies.	Yes*	No*	N/a*
		✓		
	Membership subscriptions which gives a member the right to buy services or other benefits are recognised as income earned from the provision of goods and services as income from charitable activities.	Yes*	No*	N/a*
				✓
Settlement of insurance claims	Insurance claims are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP) and are included as an item of other income in the SoFA.	Yes*	No*	N/a*
				✓
Investment gains and losses	This includes any realised or unrealised gains or losses on the sale of investments and any gain or loss resulting from revaluing investments to market value at the end of the year.	Yes*	No*	N/a*
				✓
2.2 EXPENDITURE AND LIABILITIES				
Liability recognition	Liabilities are recognised where it is more likely than not that there is a legal or constructive obligation committing the charity to pay out resources and the amount of the obligation can be measured with reasonable certainty.	Yes*	No*	N/a*
		✓	✓	✓
Governance and support costs	Support costs have been allocated between governance costs and other support. Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice.	Yes*	No*	N/a*
				✓
	Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, eg allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.	Yes*	No*	N/a*
				✓
Grants with performance conditions	Where the charity gives a grant with conditions for its payment being a specific level of service or output to be provided, such grants are only recognised in the SoFA once the recipient of the grant has provided the specified service or output.	Yes*	No*	N/a*
				✓
Grants payable without performance conditions	Where there are no conditions attaching to the grant that enables the donor charity to realistically avoid the commitment, a liability for the full funding obligation must be recognised.	Yes*	No*	N/a*
				✓
Redundancy cost	The charity made no redundancy payments during the reporting period.	Yes*	No*	N/a*
				✓
Deferred income	No material item of deferred income has been included in the accounts.	Yes*	No*	N/a*
				✓
Creditors	The charity has creditors which are measured at settlement amounts less any trade discounts	Yes*	No*	N/a*
			✓	
Provisions for liabilities	A liability is measured on recognition at its historical cost and then subsequently measured at the best estimate of the amount required to settle the obligation at the reporting date	Yes*	No*	N/a*
				✓
Basic financial instruments	The charity accounts for basic financial instruments on initial recognition as per paragraph 10.7 FRS102 SORP. Subsequent measurement is as per paragraphs 11.17 to 11.19, FRS102 SORP.	Yes*	No*	N/a*
				✓

2.3 ASSETS

Tangible fixed assets for use by charity

These are capitalised if they can be used for more than one year, and cost at least

They are valued at cost.

The depreciation rates and methods used are disclosed in note 14.

£2,500		
Yes*	No*	N/a*
		✓

Intangible fixed assets

The charity has intangible fixed assets, that is, non-monetary assets that do not have physical substance but are identifiable and are controlled by the charity through custody or legal rights. The amortisation rates and methods used are disclosed in note 15.

They are valued at cost.

Yes*	No*	N/a*
		✓
Yes*	No*	N/a*
		✓

Heritage assets

The charity has heritage assets, that is, non-monetary assets with historic, artistic, scientific, technological, geophysical or environmental qualities that are held and maintained principally for their contribution to knowledge and culture. The depreciation rates and methods used as disclosed in note 16.

They are valued at cost.

Yes*	No*	N/a*
		✓
Yes*	No*	N/a*
		✓

Investments

Fixed asset investments in quoted shares, traded bonds and similar investments are valued at initially at cost and subsequently at fair value (their market value) at the year end. The same treatment is applied to unlisted investments unless fair value cannot be measured reliably in which case it is measured at cost less impairment.

Investments held for resale or pending their sale and cash and cash equivalents with a maturity date of less than 1 year are treated as current asset investments

Yes*	No*	N/a*
		✓
Yes*	No*	N/a*
		✓

Stocks and work in progress

Stocks held for sale as part of non-charitable trade are measured at the lower or cost or net realisable value.

Goods or services provided as part of a charitable activity are measured at net realisable value based on the service potential provided by items of stock.

Work in progress is valued at cost less any foreseeable loss that is likely to occur on the contract.

Yes*	No*	N/a*
		✓
Yes*	No*	N/a*
		✓

Debtors

Debtors (including trade debtors and loans receivable) are measured on initial recognition at settlement amount after any trade discounts or amount advanced by the charity. Subsequently, they are measured at the cash or other consideration expected to be received.

Yes*	No*	N/a*
		✓
Yes*	No*	N/a*
		✓

Current asset investments

The charity has investments which it holds for resale or pending their sale and cash and cash equivalents with a maturity date less than one year. These include cash on deposit and cash equivalents with a maturity of less than one year held for investment purposes rather than to meet short-term cash commitments as they fall due.

They are valued at fair value except where they qualify as basic financial instruments.

Yes*	No*	N/a*
		✓
Yes*	No*	N/a*
		✓

POLICIES ADOPTED ADDITIONAL TO OR DIFFERENT FROM THOSE ABOVE

NOTE 3: Income

Analysis of income		Unrestricted funds	Restricted income funds	Endowment funds	Total funds £	Prior year £
Donations	Donations and gifts	114,755	-	-	114,755	150,409
	Membership subscriptions and sponsorships which are in substance donations	29,954	-	-	29,954	25,286
	Total	144,709	-	-	144,709	175,695
TOTAL INCOME		144,709	-	-	144,709	175,695

NOTE 4: Expenditure

Analysis	This year				Last year			
	Unrestricted funds	Restricted income funds	Endowment funds	Total funds	Unrestricted funds	Restricted income funds	Endowment funds	Total funds
Expenditure on raising funds				£				£
Fundraising consultants	-	-	-	-	1,125	-	-	1,125
Total expenditure on raising funds	-	-	-	-	1,125	-	-	1,125
Expenditure on charitable activities:								
All Member Meetings, Steering Group Meetings, Room Hire, Venue Costs	600	-	-	600	-	-	-	-
Patient Voice Film	-	-	-	-	-	1,483	-	1,483
Covid Impact Report	-	-	-	-	-	800	-	800
Shared Cancer Planning Project	-	-	-	-	-	600	-	600
Patient Survey Project	7,326	-	-	7,326	-	9,600	-	9,600
Pfizer Project Support	10,020	-	-	10,020	-	6,520	-	6,520
Impact Reporting and Annual Review	1,505	-	-	1,505	-	5,520	-	5,520
Telephone	74	-	-	74	-	-	-	-
IT and Computer running expenses	443	-	-	443	-	96	-	96
Policy consultants - Policy Support	19,605	-	-	19,605	-	18,140	-	18,140
Policy Report	2,175	-	-	2,175	-	-	-	-
Subscriptions	1,384	-	-	1,384	-	933	-	933
Secretarial expenses	31,855	-	-	31,855	-	29,713	-	29,713
Insurance	556	-	-	556	533	-	-	533
Management and Administration	4,000	-	-	4,000	34,806	3,958	-	38,764
Salaries and Employers NI and Pensions	66,060	-	-	66,060	-	-	-	-
Communications and PR	2,000	-	-	2,000	9,691	-	-	9,691
Bank and credit fees	216	-	-	216	216	-	-	216
Trustees/Directors Travel	162	-	-	162	-	-	-	-
Trustee Recruitment costs and expenses	319	-	-	319	-	494	-	494
Non-Trustee Recruitment	450	-	-	450	-	-	-	-
Total expenditure on charitable activities	148,750	-	-	148,750	45,246	77,857	-	123,103
Other								
Independent Examiner	2,400	-	-	2,400	1,800	-	-	1,800
Total other expenditure	2,400	-	-	2,400	1,800	-	-	1,800
TOTAL EXPENDITURE	151,150	-	-	151,150	48,171	77,857	-	126,028

NOTE 5: Details of certain types of expenditure

Note 5.1 Fees for examination of the accounts

Please provide details of the amount paid for any statutory external scrutiny of accounts and other services provided by your independent examiner. If nothing was paid please enter '0' in the appropriate box(es).

Independent examiner's fees

This year £	Last year £
2,400	1,800

NOTE 6: Paid Employees

Please complete this note if the charity has any employees (transactions with Trustees dealt with in Note 28)

6.1 Staff Costs

	This year £	Last year £
Salaries and wages	60,000	-
Social security costs	3,060	-
Pension costs (defined contribution scheme)	3,000	-
Other employee benefits	-	-
Total staff costs	66,060	-

Please give details of the number of employees whose total employee benefits (excluding employer pension costs)

No employees received employee benefits (excluding employer

Band	Number of employees	
	This year	Last year
£60,000 to £69,999	1	-

	This year £	Last year £
Please provide the total amount paid to key management personnel	60,000	-

6.2 Average head count in the year

The parts of the charity in which the employees work

	This year Number	Last year Number
Fundraising	-	-
Charitable Activities	-	-
Governance	1	-
Other	-	-
Total	1	-

NOTE 7: Creditors and accruals

Please complete this note if the charity has any creditors or accruals.

7.1 Analysis of creditors

	Amounts falling due within one year		Amounts falling due after more than one year	
	This year £	Last year £	This year £	Last year £
Accruals and deferred income	25,290	1,800	-	-
Other creditors	370	-	-	-
Total	25,660	1,800	-	-

NOTE 8: Cash at bank and in hand

Cash at bank and on hand
Total

This year £	Last year £
135,949	118,530
135,949	118,530

NOTE 9: Fair value of assets and liabilities

9.1 Please provide details of the charity's exposure to credit risk (the risk of incurring a loss due to a debtor not paying what is owed), liquidity risk (the risk of not being able to meet short term financial demands) and market risk (the risk that the value of an investment will fall due to changes in the market) arising from financial instruments to which the charity is exposed at the end of the reporting period and explain how the charity manages those risks.

This year	Last year
Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.	Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.

9.2 Please give details of the amount of change in the fair value of basic financial instruments (debtors, creditors, investments (see section 11, FRS 102 SORP)) measured at fair value through the SoFA that is attributable to changes in credit risk.

Not applicable	Not applicable
----------------	----------------

NOTE 10: Charity funds

10.1 Details of material funds held and movements during the CURRENT reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	116,730	144,709	(151,150)	-	-	110,289
Total Funds as per balance sheet			116,730	144,709	(151,150)	-	-	110,289

Yes* ☒ No* ☒

Fund balances carried forward include assets and liabilities denominated in a foreign currency

If yes, please state the basis on which the assets and/or liabilities have been translated into sterling (or the currency in which the accounts are drawn up).

10.2 Details of material funds held and movements during the PREVIOUS reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	67,063	97,838	(48,171)	-	-	116,730
Covid-19 Restricted Fund	R	Restricted to Core Charitable Expenditure	-	77,857	(77,857)	-	-	-
Total Funds as per balance sheet			67,063	175,695	(126,028)	-	-	116,730

Yes*	No*
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Fund balances carried forward include assets and liabilities denominated in a foreign currency

NOTE 11: Transactions with trustees and relates parties

If the charity has any transactions with related parties (other than the trustee expenses explained in guidance notes) details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box or "False" if there are transactions to report.

11.1 Trustee remuneration and benefits

This year

None of the trustees have been paid any remuneration or received any other benefits from an employment with their charity or a related entity (True or False)

TRUE

11.2 Trustees' expenses

If the charity has paid trustees expenses for fulfilling their duties, details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box below. If there are transactions to report, please enter "False".

No trustee expenses have been incurred (True or False)

TRUE

Type of expenses reimbursed	This year	Last year
	£	£
Travel	-	-
TOTAL	-	-

Please provide the number of trustees reimbursed for expenses or who had expenses paid by the charity

0

0

11.3 Transaction(s) with related parties

Please give details of any transaction undertaken by (or on behalf of) the charity in which a related party has a material interest, including where funds have been held as agent for related parties. If there are no such transactions, please enter 'true' in the box provided.

This year

There have been no related party transactions in the reporting period (True or False)

TRUE

Last year

There have been no related party transactions in the reporting period (True or False)

TRUE



Administrative details

TRUSTEES

Jonathan Pearce, Chair
Helen Morement
Rebecca Porta
Nic Puntis
Christopher Walden
Anna Evans
Dr Max Brodermann
Michael Draeger
Sophie Davies

EXECUTIVE OFFICERS

Baroness Morgan of Drefelin President
Jane Lyons Chief executive
Jonathan Pearce Company secretary

REGISTERED OFFICE

c/o Teenage Cancer Trust 3rd Floor,
93 Newman Street, London W1T 3EZ

WEBSITE

www.cancer52.org.uk

BANKERS

Co-operative Bank



References

- ¹ National Cancer Registration and Analysis Service (NCRAS) by Public Health England figures. May 2019
- ² Cancer Statistics for the UK. Cancer Research UK. Available: <https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk#heading-Zero>.
- ³ Cancer52 membership research, conducted April 2019
- ⁴ Average email open rates for 2022. Smart Insights. Available: <https://www.smartinsights.com/email-marketing/email-communications-strategy/statistics-sources-for-email-marketing/#q4>
- ⁵ Long Term Plan. NHS. Available: www.longtermplan.nhs.uk/areas-of-work/cancer
- ⁶ Clearing the backlog caused by the pandemic - Health and Social Care Committee (parliament.uk). Available: <https://publications.parliament.uk/pa/cm5802/cmselect/cmhealth/599/report.html>
- ⁷ Health and Social Care Committee report on Cancer services. Cancer52 response. Available: <https://www.cancer52.org.uk/single-post/health-and-social-care-committee-report-on-cancer-services>
- ⁸ 10-Year Cancer Plan. One Cancer Voice (OCV) response to the Call for Evidence. Available: <https://www.cancer52.org.uk/single-post/10-year-cancer-plan-one-cancer-voice-consensus-statement>
- ⁹ The NICE methods of health technology evaluation: the case for change. Cancer52 response. Available: <https://www.cancer52.org.uk/single-post/nice-methods-review>
- ¹⁰ 10-Year Cancer Plan. Call for Evidence. Available: <https://www.gov.uk/government/consultations/10-year-cancer-plan-call-for-evidence>
- ¹¹ 10-Year Cancer Plan. Cancer52 response to the Call for Evidence. Available: <https://www.cancer52.org.uk/single-post/10-year-cancer-plan-cancer52-response-to-the-call-for-evidence>
- ¹² Do You C Us? website: <https://www.doyocus.org.uk/>
- ¹³ Together for Antibiotics. ABPI. Available: <https://www.togetherforantibiotics.org.uk>
- ¹⁴ ABPI AMR: Resources (togetherforantibiotics.org.uk): https://www.togetherforantibiotics.org.uk/resources/?3b293f58a0d649e6a204d1476bc6a631_cat=Cancer52&3b293f58a0d649e6a204d1476bc6a631_page=1
- ¹⁵ Policy on Working with the Pharmaceutical & Healthcare Industry. Microsoft Word - Cancer52 Pharmaco Policy March 2020 Amended after March Board FINAL

List of charity members 2021/22

ACLT (African Caribbean Leukaemia Trust)
www.aclt.org

Act for Cancer
www.actforcancer.org.uk

Action Against Heartburn
www.actionagaintheartburn.org.uk

Action Bladder Cancer UK
www.actionbladdercanceruk.org

Action Kidney Cancer
www.kcsn.org.uk

Action on Womb Cancer
www.actiononwombcancer.org.uk

Alike
www.alike.org.uk

ALK Positive Lung Cancer
www.alkpositive.org.uk

AMMF – The Cholangiocarcinoma Charity
www.ammf.org.uk

Anthony Nolan
www.anthonynolan.org

Association for Multiple Endocrine Neoplasia Disorders (AMEND)
www.amend.org.uk

Baggy Trousers UK
www.baggytrousersuk.org

Balls to Cancer
www.ballstocancer.co.uk

Barrett's Oesophagus UK
www.barrettscampaign.org.uk

Blood Cancer UK
www.bloodcancer.org.uk

Bone Cancer Research Trust
www.bcrct.org.uk

Bowel Research UK
www.bowelresearchuk.org

Brain Tumour Research
www.braintumourresearch.org

Brain Tumour Research Campaign (Wayahead)
www.btrc-charity.org

Braintrust
www.braintrust.org.uk

British Lymphology Society (BLS)
www.thebls.com

British Thyroid Foundation (BTF-thyroid)
www.btf-thyroid.org

Butterfly Thyroid Cancer Trust (BTCT)
www.butterfly.org.uk

Cancer Laryngectomy Trust
www.cancerlt.org

Cancer of Unknown Primary (CUP)
Foundation – Jo's friends
www.cupfoundjo.org

Childhood Eye Cancer Trust (CHECT)
www.checht.org.uk

Children's Cancer and Leukaemia Group (CCLG)
www.cclg.org.uk

Chordoma UK
www.chordoma-uk.org

Chris Lucas Trust
www.chrislucastrust.com

Chronic Myeloid Leukaemia (CML) Support Group UK
www.cmlsupport.org.uk

CLL Support Association
www.clisupport.org.uk

Debbie Fund
www.debbiefund.org

DKMS
www.dkms.org.uk

EHE Rare Cancer Charity (UK)
www.ehercc.org.uk

Ellen MacArthur Cancer Trust
www.ellenmacarthurcancertrust.org

Fight Bladder Cancer
www.fightbladdercancer.co.uk

GIST Cancer UK
www.gistcancer.org.uk

Grace Kelly Childhood Cancer Trust
www.gkcct.org

GUTS Charity
www.gutscharity.org.uk

Heartburn Cancer UK
www.heartburncanceruk.org

HLRCC Family Alliance
www.hlrccinfo.org

ICPV Independent Cancer Patients' Voice
www.icpv.org.uk

International Brain Tumour Alliance (IBTA)
www.theibta.org

It's In The Bag Cancer Support Ltd
www.itsinthebag.org.uk

It's on the Ball
www.itsontheball.org

Jo's Cervical Cancer Trust
www.jostrust.org.uk

Kidney Cancer UK
www.kcuk.org.uk

Live Through This
www.livethroughthis.co.uk

Leukaemia CARE
www.leukaemiacare.org.uk

Leukaemia UK
www.leukaemiauk.org.uk

Lymphoedema Support Network
www.lymphoedema.org

Lymphoma Action
www.lymphoma-action.org.uk

Maggie's Cancer Caring Centres
www.maggies.org

MDS (Myelodysplastic Syndromes) UK Patient Support Group
www.mdspatientsupport.org.uk

Melanoma Focus
www.melanomafocus.com

Melanoma UK
www.melanomauk.org.uk

Mesothelioma UK
www.mesothelioma.uk.com

MPN Voice
www.mpnvoice.org.uk

Mummy's Star
www.mummystar.org

Myeloma UK
www.myeloma.org.uk

Neuroblastoma UK
www.neuroblastoma.org.uk

Neuroendocrine Cancer UK (NCUK)
www.neuroendocrinecancer.org.uk

North West Cancer Research
www.nwcr.org

OcuMel UK
www.ocumeluk.org

Oracle Cancer Trust
www.oraclecancertrust.org

Orchid Cancer Appeal
www.orchid-cancer.org.uk

Ovacome, The Ovarian Cancer Support Network
www.ovacome.org.uk

Ovarian Cancer Action
www.ovarian.org.uk

Pancreatic Cancer Action
www.pancreaticcanceraction.org

Pancreatic Cancer UK (PCUK)
www.pancreaticcancer.org.uk

Paul's Cancer Support Centre
www.pauls.org.uk

Pelvic Radiation Disease Association (PRDA)
www.prda.org.uk

Penny Brohn UK
www.pennybrohn.org.uk

PLANETS
www.planetscharity.org

Pseudomyxoma Survivor
www.pseudomyxomasurvivor.org

Salivary Gland Cancer UK
www.salivaryglandcancer.uk

Sarcoma UK
www.sarcoma.org.uk

Shine Cancer Support
www.shinecancersupport.org

Solving Kids' Cancer
www.solvingkidscancer.org.uk

Target Ovarian Cancer
www.targetovariancancer.org.uk

Team Margot Foundation
www.teammargot.com

Teenage Cancer Trust (TCT)
www.teenagecancertrust.org

The Brain Tumour Charity
www.thebraintumourcharity.org

The Charley Ashton Foundation
www.thecharleyashtonfoundation

The Eve Appeal
www.eveappeal.org.uk

The Mavis Nye Foundation
www.mavisnyefoundation.com

The Myrovlytis Trust
www.myrovlytistrust.org

The Northern Ireland Rare Disease Partnership
www.nirdp.org.uk

The Robin Cancer Trust
www.therobincancertrust.org

The Urology Foundation
www.theurologyfoundation.org

ThymicUK
www.thymicuk.org

Thyroid Cancer Support Group Wales
www.thyroidsupportwales.co.uk

Tom Bowdidge Youth Cancer Foundation
www.tombowdidgefoundation.org

Trekstock
www.trekstock.com

UCARE
www.ucare-cancer.org.uk

UK Masto
www.ukmasto.org

Urostomy Association
www.urostomyassociation.org.uk

VHL UK/Ireland
www.vhl-uk-ireland.org

Wellbeing of Women
www.wellbeingofwomen.org.uk

Wendy Gough Cancer Awareness Foundation
www.wgcaf.com

WMUK
www.wmuk.org.uk

Womb Cancer Info
www.wombcancerinfo.wixsite.com/home

Womb Cancer Support UK
www.wombcancersupportuk.weebly.com

Yorkshire Cancer Community
www.yorkshirecancercommunity.co.uk

Young Lives Vs. Cancer
www.younglivesvscancer.org.uk



Cancer52 is registered as a charity in England and Wales, **Charity No. 1174569** and as a company limited by guarantee in England and Wales, **Company No. 07994413**

If we **work together**
we can make as much noise as the big four

